Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Toon andere (1) versies

BACKGROUND: For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years inste...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Bonfill, X, Bradbury, J, Clarke, M, Collins, R, Davis, SR, Delmestri, A, Forbes, J, Haddad, P, Hou, M, Inbar, M, Khaled, H, Kielanowska, J, Kwan, W, Mathew, B, Mittra, I, Müller, B
Formaat: Journal article
Taal:English
Gepubliceerd in: 2013

Gelijkaardige items